Compositions and Methods for Preventing or Treating Diseases, Conditions, or Processes Characterized by Aberrant Fibroblast Proliferation and Extracellular Matrix Deposition
申请人:MOERAE MATRIX, INC.
公开号:US20160136234A1
公开(公告)日:2016-05-19
The described invention provides compositions and methods for reducing progression of a fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the progression of the fibrosis being characterized by aberrant fibroblast proliferation and extracellular matrix deposition in the tissue. The method includes administering a therapeutic amount of a pharmaceutical composition containing a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce progression of the fibrosis, to treat remodeling of the tissue, or a combination thereof.
描述的发明提供了一种用于减少主体选定组织中的纤维化进展的组成和方法,该选定组织来自肝纤维化、肾纤维化或血管纤维化,纤维化的进展在组织中以异常成纤维细胞增殖和细胞外基质沉积为特征。该方法包括施用含有具有氨基酸序列YARAAARQARAKALARQLGVAA(SEQ ID NO: 1)或其功能等效物的多肽的药物治疗量,以及药学上可接受的载体,其中多肽的治疗量有效于减少纤维化的进展,治疗组织的重塑,或其组合。
[EN] COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE
申请人:UNIV CASE WESTERN RESERVE
公开号:WO2018218251A1
公开(公告)日:2018-11-29
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
[EN] COMPOUNDS AND METHODS USE<br/>[FR] COMPOSÉS ET MÉTHODES D'UTILISATION
申请人:SIGNUM BIOSCIENCES INC
公开号:WO2018132759A1
公开(公告)日:2018-07-19
The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.
SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI
申请人:DELIVERSIR LTD.
公开号:US20160039850A1
公开(公告)日:2016-02-11
The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.
Novel self-immolative dendritic compounds which have a plurality of cleavable trigger units and hence can release a chemical moiety at their focal point upon a multi-triggering mechanism are disclosed. The novel self-immolative dendritic compounds are gated by a molecular logic gate, being either an AND or OR logic gate and hence can be beneficially used in a variety of biological, chemical and physical applications. Processes of preparing, compositions containing and methods utilizing the novel dendritic compounds are further disclosed.